

Accepted Manuscript

Systematic or Meta-analysis Studies

Aged patients with metastatic castration resistant prostate cancer: should we treat with chemotherapy?

Miguel Ángel Climent, M^a Dolores Torregrosa, Sergio Vazquez, Regina Gironés, José Angel Arranz

PII: S0305-7372(17)30044-0
DOI: <http://dx.doi.org/10.1016/j.ctrv.2017.03.007>
Reference: YCTRV 1619

To appear in: *Cancer Treatment Reviews Cancer Treatment Reviews*

Received Date: 2 February 2017
Revised Date: 20 March 2017
Accepted Date: 22 March 2017

Please cite this article as: Climent, M.A., Torregrosa, M.D., Vazquez, S., Gironés, R., Arranz, J.A., Aged patients with metastatic castration resistant prostate cancer: should we treat with chemotherapy?, *Cancer Treatment Reviews Cancer Treatment Reviews* (2017), doi: <http://dx.doi.org/10.1016/j.ctrv.2017.03.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: Aged patients with metastatic castration resistant prostate cancer: should we treat with chemotherapy?

Authors: Miguel Ángel Climent^a, M^a Dolores Torregrosa^b, Sergio Vazquez^c, Regina Gironés^d, José Angel Arranz^e.

a. Medical Oncology Service, Instituto Valenciano de Oncología (IVO), Valencia, Spain. macliment@fivo.org.

b. Medical Oncology Unit, Hospital Universitario Dr.Peset, Valencia, Spain. marilotorre@gmail.com

c. Medical Oncology Service, Hospital Universitario Lucus Augusti, Lugo, Spain. Sergio.Vazquez.Estevez@sergas.es.

d. Medical Oncology Unit, Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain. girones_reg@gva.es

e. Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. jarranza.oncomed@gmail.com

Corresponding author. Department of oncology, Instituto Valenciano de Oncología (IVO), C/Beltrán Báguena, 8, 46009, Valencia, Spain.

E-mail address: macliment@fivo.org (Miguel Ángel Climent).

Suggested highlights

- Geriatric assessment is crucial for a successful treatment of aged-patients with CRPC.
- Young and aged well-fit prostate cancer patients could benefit from chemotherapy.
- Vulnerable or frail patients may require weekly or biweekly taxane-based chemotherapy.

Conflict-of-interest statement: SV has been on the speakers/advisory board from Sanofi, Astellas, Janssen and Bayer. The other authors declare no conflicts of interest.

Download English Version:

<https://daneshyari.com/en/article/5697666>

Download Persian Version:

<https://daneshyari.com/article/5697666>

[Daneshyari.com](https://daneshyari.com)